Assignee
INIPHARM INC
US·2 granted patents·10 pending applications·1 citations·filing 2021–2025
Top patents by PatentIndex Score
12 records- 0184US11827619B2Dichlorophenol HSD17B13 inhibitors and uses thereofINIPHARM INC·Filed 2023·Granted Nov 28, 2023·1 cites·28 claims
- 0271US12227489B2Dichlorophenol HSD17B13 inhibitors and uses thereofINIPHARM INC·Filed 2023·Granted Feb 18, 2025·0 cites·28 claims
- 0360US2025376457A1Dichlorophenol hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2025·Application pending·0 cites
- 0455US2025320186A1Hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2023·Application pending·0 cites
- 0554US2025100993A12-substituted thiazole hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2023·Application pending·0 cites
- 0650US2024208929A1Hydroxypyridine hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2022·Application pending·0 cites
- 0750US2024208959A1Thiazole/isothiazole hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2022·Application pending·0 cites
- 0849US2023416802A1Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatmentINIPHARM INC·Filed 2021·Application pending·0 cites
- 0947US2023286923A1Quinazolinone hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2021·Application pending·0 cites
- 1047US2023278978A1Thiophene hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2021·Application pending·0 cites
- 1146US2025216407A1Liver disease treatment and assessment using oxylipinsINIPHARM INC·Filed 2023·Application pending·0 cites
- 1245US2023150940A1Hsd17b13 inhibitors and uses thereofINIPHARM INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →